Literature DB >> 30569443

Familial hyperaldosteronism type III a novel case and review of literature.

Natividad Pons Fernández1, Francisca Moreno2, Julia Morata3, Ana Moriano3, Sara León2, Carmen De Mingo2, Ángel Zuñiga2, Fernando Calvo3.   

Abstract

Less than 15% of hypertension cases in children are secondary to a primary hyperaldosteronism. This is idiopathic in 60% of the cases, secondary to a unilateral adenoma in 30% and 10% remaining by primary adrenal hyperplasia, familial hyperaldosteronism, ectopic aldosterone production or adrenocortical carcinoma.To date, four types of familial hyperaldosteronism (FH I to FH IV) have been reported. FH III is caused by germline mutations in KCNJ5, encoding the potassium channel Kir3.4. The mutations cause the channel to lose its selectivity for potassium, allowing large quantities of sodium to enter the cell. As a consequence, the membrane depolarizes, voltage-gated calcium channels open, calcium enters the cell, initiating the cascade that leads to aldosterone synthesis. Somatic mutations in KCNJ5 has also been described in aldosterone-producing adenomas. The most frequent presentation of FH III is with severe hyperaldosteronism symptoms and resistance to pharmacological therapy which leads to bilateral adrenalectomy. We will review current literature and describe a child with FH III due to a novel de novo deletion in KCNJ5 with wild phenotype as a sign of clinical variability of this disease.

Entities:  

Keywords:  Hypertension; KCNJ5; Kir3.4; Mineralocorticoid receptor; Primary hyperaldosteronism

Year:  2019        PMID: 30569443     DOI: 10.1007/s11154-018-9481-0

Source DB:  PubMed          Journal:  Rev Endocr Metab Disord        ISSN: 1389-9155            Impact factor:   6.514


  42 in total

Review 1.  Familial hyperaldosteronism type III.

Authors:  S Monticone; M Tetti; J Burrello; F Buffolo; R De Giovanni; F Veglio; T A Williams; P Mulatero
Journal:  J Hum Hypertens       Date:  2017-04-27       Impact factor: 3.012

Review 2.  Hyperaldosteronism: How to Discriminate Among Different Disease Forms?

Authors:  Valentina Crudo; Silvia Monticone; Jacopo Burrello; Fabrizio Buffolo; Martina Tetti; Franco Veglio; Paolo Mulatero
Journal:  High Blood Press Cardiovasc Prev       Date:  2016-05-02

3.  SFE/SFHTA/AFCE Consensus on Primary Aldosteronism, part 2: First diagnostic steps.

Authors:  Claire Douillard; Pascal Houillier; Juerg Nussberger; Xavier Girerd
Journal:  Ann Endocrinol (Paris)       Date:  2016-05-10       Impact factor: 2.478

Review 4.  Expression of CYP11B2 in Aldosterone-Producing Adrenocortical Adenoma: Regulatory Mechanisms and Clinical Significance.

Authors:  Yasuhiro Nakamura; Yuto Yamazaki; Yuta Tezuka; Fumitoshi Satoh; Hironobu Sasano
Journal:  Tohoku J Exp Med       Date:  2016-11       Impact factor: 1.848

5.  Clinical and pathological diversity of primary aldosteronism, including a new familial variety.

Authors:  R D Gordon; M Stowasser; T J Tunny; S A Klemm; W L Finn; A L Krek
Journal:  Clin Exp Pharmacol Physiol       Date:  1991-05       Impact factor: 2.557

6.  Primary aldosteronism: emerging trends.

Authors:  Sandi-Jo Galati; Sarah M Hopkins; Khadeen C Cheesman; Rachel A Zhuk; Alice C Levine
Journal:  Trends Endocrinol Metab       Date:  2013-06-21       Impact factor: 12.015

7.  Measurement of peripheral plasma 18-oxocortisol can discriminate unilateral adenoma from bilateral diseases in patients with primary aldosteronism.

Authors:  Fumitoshi Satoh; Ryo Morimoto; Yoshikiyo Ono; Yoshitsugu Iwakura; Kei Omata; Masataka Kudo; Kei Takase; Kazumasa Seiji; Hidehiko Sasamoto; Seijiro Honma; Mitsunobu Okuyama; Kouwa Yamashita; Celso E Gomez-Sanchez; William E Rainey; Yoichi Arai; Hironobu Sasano; Yasuhiro Nakamura; Sadayoshi Ito
Journal:  Hypertension       Date:  2015-03-16       Impact factor: 10.190

8.  Novel somatic mutations in primary hyperaldosteronism are related to the clinical, radiological and pathological phenotype.

Authors:  Ute I Scholl; James M Healy; Anne Thiel; Annabelle L Fonseca; Taylor C Brown; John W Kunstman; Matthew J Horne; Dimo Dietrich; Jasmin Riemer; Seher Kücükköylü; Esther N Reimer; Anna-Carinna Reis; Gerald Goh; Glen Kristiansen; Amit Mahajan; Reju Korah; Richard P Lifton; Manju L Prasad; Tobias Carling
Journal:  Clin Endocrinol (Oxf)       Date:  2015-09-23       Impact factor: 3.478

9.  Further evidence for linkage of familial hyperaldosteronism type II at chromosome 7p22 in Italian as well as Australian and South American families.

Authors:  Norlela Sukor; Paolo Mulatero; Richard D Gordon; Albertina So; David Duffy; Chiara Bertello; Livia Kelemen; Yvette Jeske; Franco Veglio; Michael Stowasser
Journal:  J Hypertens       Date:  2008-08       Impact factor: 4.844

10.  a Novel Y152C KCNJ5 mutation responsible for familial hyperaldosteronism type III.

Authors:  Silvia Monticone; Namita G Hattangady; David Penton; Carlos M Isales; Michael A Edwards; Tracy A Williams; Christina Sterner; Richard Warth; Paolo Mulatero; William E Rainey
Journal:  J Clin Endocrinol Metab       Date:  2013-09-13       Impact factor: 5.958

View more
  2 in total

1.  Monogenic forms of low-renin hypertension: clinical and molecular insights.

Authors:  Priyanka Khandelwal; Jaap Deinum
Journal:  Pediatr Nephrol       Date:  2021-08-20       Impact factor: 3.651

Review 2.  Pathogenesis of Primary Aldosteronism: Impact on Clinical Outcome.

Authors:  Lucas S Santana; Augusto G Guimaraes; Madson Q Almeida
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-23       Impact factor: 6.055

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.